Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Bissonnette

Showing results (131-140 of 222) with videos related to

Pageof 23
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|February 22, 2025
Mission impossible? Caveats in interpreting and comparing long-term efficacy in biologic studies for moderate-to-severe plaque psoriasisRichard G Langley, Alexander Egeberg, Melinda Gooderham, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 9, 2024
Psychometric validation of the Psoriasis Symptom Scale, Functional Assessment of Chronic Illness Therapy-Fatigue and pain-Visual Analogue Scale in patients with generalized pustular psoriasisA David Burden, Robert Bissonnette, Milena Anatchkova, et al.
JAMA Dermatology|April 15, 2026
International Eczema Council Definitions of Low Disease Activity and Remission in Atopic Dermatitis: A Consensus StatementJoseph F Merola, Beth A Childs, Brooke R Bartley, et al.
Journal of Dermatological Science|October 17, 2016
Palmoplantar pustular psoriasis (PPPP) is characterized by activation of the IL-17A pathwayRobert Bissonnette, Judilyn Fuentes-Duculan, Shunya Mashiko, et al.
JAMA Dermatology|July 10, 2024
Dupilumab in Adults With Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension StudyLisa A Beck, Robert Bissonnette, Mette Deleuran, et al.
The Journal of Investigative Dermatology|October 16, 2025
Randomized Controlled Trial of the Topical Jak Inhibitor Delgocitinib Cream in Patients with Frontal Fibrosing AlopeciaAubrey Martin, Neda Shokrian, Kristen J Kelley, et al.
Journal of the American Academy of Dermatology|April 13, 2023
Crisaborole reverses dysregulation of the mild to moderate atopic dermatitis proteome toward nonlesional and normal skinMadeline Kim, Ester Del Duca, Julia Cheng, et al.
Archives of Dermatology|January 21, 2004
Photodynamic therapy of multiple nonmelanoma skin cancers with verteporfin and red light-emitting diodes: two-year results evaluating tumor response and cosmetic outcomesHarvey Lui, Lori Hobbs, Whitney D Tope, et al.
The Journal of Allergy and Clinical Immunology|February 28, 2017
Molecular signatures order the potency of topically applied anti-inflammatory drugs in patients with atopic dermatitisEmma Guttman-Yassky, Benjamin Ungar, Kunal Malik, et al.
Advances in Therapy|January 21, 2026
Dupilumab Treatment Up to 5 Years Shows No Clinically Meaningful Changes in Laboratory Parameters in Adults with Moderate-to-Severe Atopic DermatitisEric L Simpson, Robert Bissonnette, Mette Deleuran, et al.
Pageof 23

Showing results (131-140 of 222) with videos related to

Sort By:
Pageof 23
Journal of the European Academy of Dermatology and Venereology : JEADV|February 22, 2025
Mission impossible? Caveats in interpreting and comparing long-term efficacy in biologic studies for moderate-to-severe plaque psoriasisRichard G Langley, Alexander Egeberg, Melinda Gooderham, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 9, 2024
Psychometric validation of the Psoriasis Symptom Scale, Functional Assessment of Chronic Illness Therapy-Fatigue and pain-Visual Analogue Scale in patients with generalized pustular psoriasisA David Burden, Robert Bissonnette, Milena Anatchkova, et al.
JAMA Dermatology|April 15, 2026
International Eczema Council Definitions of Low Disease Activity and Remission in Atopic Dermatitis: A Consensus StatementJoseph F Merola, Beth A Childs, Brooke R Bartley, et al.
Journal of Dermatological Science|October 17, 2016
Palmoplantar pustular psoriasis (PPPP) is characterized by activation of the IL-17A pathwayRobert Bissonnette, Judilyn Fuentes-Duculan, Shunya Mashiko, et al.
JAMA Dermatology|July 10, 2024
Dupilumab in Adults With Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension StudyLisa A Beck, Robert Bissonnette, Mette Deleuran, et al.
The Journal of Investigative Dermatology|October 16, 2025
Randomized Controlled Trial of the Topical Jak Inhibitor Delgocitinib Cream in Patients with Frontal Fibrosing AlopeciaAubrey Martin, Neda Shokrian, Kristen J Kelley, et al.
Journal of the American Academy of Dermatology|April 13, 2023
Crisaborole reverses dysregulation of the mild to moderate atopic dermatitis proteome toward nonlesional and normal skinMadeline Kim, Ester Del Duca, Julia Cheng, et al.
Archives of Dermatology|January 21, 2004
Photodynamic therapy of multiple nonmelanoma skin cancers with verteporfin and red light-emitting diodes: two-year results evaluating tumor response and cosmetic outcomesHarvey Lui, Lori Hobbs, Whitney D Tope, et al.
The Journal of Allergy and Clinical Immunology|February 28, 2017
Molecular signatures order the potency of topically applied anti-inflammatory drugs in patients with atopic dermatitisEmma Guttman-Yassky, Benjamin Ungar, Kunal Malik, et al.
Advances in Therapy|January 21, 2026
Dupilumab Treatment Up to 5 Years Shows No Clinically Meaningful Changes in Laboratory Parameters in Adults with Moderate-to-Severe Atopic DermatitisEric L Simpson, Robert Bissonnette, Mette Deleuran, et al.
Pageof 23